Commercial Plant-Produced Recombinant Protein Products

Attention has recently turned to using plants as hosts for the production of commercially important proteins. The twelve case studies in this volume present successful strategies for using plants to produce industrial and pharmaceutical proteins and vaccine antigens. They examine in detail projects that have commercial potential or products that have already been commercialized, illustrating the advantages that plants offer over bacterial, fungal or animal cell-culture hosts. There are many indications that plant protein production marks the beginning of a new paradigm for the commercial production of proteins that, over the next decade, will expand dramatically.

Introduction - Plant-produced protein products.- Commercial Plant-Produced Recombinant Avidin.- Molecular farming in plants - the long road to the market.- TrypZean(TM): an animal-free alternative to bovine trypsin.- Production of Pharmaceutical Grade Recombinant Native Aprotinin and Non-Oxidized Aprotinin-Variants Under Greenhouse and Field Conditions.- Influenza virus-like particles produced in Nicotiana benthamiana protect against a lethal viral challenge in mice.- Plant-Produced Recombinant Transmission Blocking Vaccine Candidates to Combat Malaria.- An oral vaccine for TGEV immunization of pigs.- Edible Rabies Vaccines.- Newcastle disease vaccines.- An oral vaccine for hepatitis B: challenges, setbacks and breakthroughs.- Commercial Plant-Produced Recombinant Cellulases for Biomass Conversion.- Brazzein: A High Intensity Natural Sweetener.- The Future of Plant-Produced Pharmaceuticals and Industrial Proteins.